Patients’ Perceptions of Biosimilars: A Systematic Review
Author:
Funder
Peking Union Medical College
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Link
https://link.springer.com/content/pdf/10.1007/s40259-023-00620-7.pdf
Reference93 articles.
1. Tinsley SM, Grande C, Olson K, Plato L, Jacobs I. Potential of biosimilars to increase access to biologics: considerations for advanced practice providers in oncology. J Adv Pract Oncol. 2018;9(7):699. https://doi.org/10.6004/jadpro.2018.9.7.2.
2. Antman EM, Creager MA, Houser SR, Warner JJ, Konig M. American Heart Association principles on the accessibility and affordability of drugs and biologics: a presidential advisory from the American Heart Association. Circulation. 2017;136(24):e441–7. https://doi.org/10.1161/CIR.0000000000000551.
3. Kirchhoff CF, Wang XZM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696–705. https://doi.org/10.1002/bit.26438.
4. Safdar A, Butt MH, Ahmad A, Zaman M. Progress in oncology biosimilars till 2020: scrutinizing comparative studies of biosimilar monoclonal antibodies. J Oncol Pharm Pract. 2021;27(5):1195–204. https://doi.org/10.1177/10781552211016083.
5. Triantafyllidi E, Triantafillidis JK. Systematic review on the use of biosimilars of trastuzumab in HER2+ breast cancer. Biomedicines. 2022;10(8):2045. https://doi.org/10.3390/biomedicines10082045.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers;Exploration of Musculoskeletal Diseases;2024-09-10
2. A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects;Drug Design, Development and Therapy;2024-08
3. Biosimilars in the Era of Artificial Intelligence—International Regulations and the Use in Oncological Treatments;Pharmaceuticals;2024-07-10
4. Conocimiento de la terapia biológica en pacientes con enfermedades inmunomediadas. Estudio BIOINFO;Farmacia Hospitalaria;2024-06
5. Patient’s and Consultant’s Views and Perceptions on Switching from an Originator Biologic to Biosimilar Medication: A Qualitative Study;Pharmacy;2024-04-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3